Skip to main content

Acute-graft-versus-host Disease

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
NCT03805789 | Phase 2 | Interventional

This study is a Phase 2/3 prospective, double-blind, randomized, multi-center, placebo-controlled study for prevention of acute GVHD (aGVHD) in subjects undergoing an allogeneic hematopoietic cell transplant (HCT).

Trial Information
20 Sites
310 Participants
12 Years

If interested, contact for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Scottsdale HH Cancer Transplant
Scottsdale,Arizona,United States,85258
Emory University
Atlanta,Georgia,United States,30322
University of Kansas Cancer Center
Westwood,Kansas,United States,66205
University of Michigan
Ann Arbor,Michigan,United States,48109
Duke University Medical Center
Durham,North Carolina,United States,27710
Cleveland Cancer Center (University Hospitals UH Seidman Cancer Center Ireland Cancer Center)
Cleveland,Ohio,United States,44106
Centennial Medical Center (TriStar BMT)
Nashville,Tennessee,United States,37203
The University of TexasMD Anderson Cancer Center
San Antonio,Texas,United States,77030
Methodist Hospital
San Antonio,Texas,United States,78229
Primary Children's Hospital
Salt Lake City,Utah,United States,84113
Seattle Cancer Care Alliance
Seattle,Washington,United States,98109
Royal Brisbane and Women's Hospital
University Essen
Uniklinik Kln, lnnere Mediz
Complejo Hospitalario de Navarra
Hospital Universitario Vall d
Hospital Regional Universitario de Malaga
Universitario de Salamanca
Hospital Universitario Marqus
Santander,Spain,M20 4BX
The Christie NHS Foundation
Manchester,United Kingdom

Study Eligibility Criteria

  • Male or female subjects, ≥12 years of age (≥ 18 years of age for subjects at German sites only), undergoing HCT for hematological malignancies, including leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome and myeloproliferative neoplasms
  • Planned myeloablative conditioning regimen
  • Prior autologous or allogeneic HCT
  • T-cell depleted transplant or planned use of anti-T cell antibody therapy either ex vivo or in vivo (ie, anti-thymocyte globulin [ATG], alemtuzumab) for GVHD prophylaxis
  • Planned umbilical cord blood (UCB) transplant

Additional Studies

Additional studies can be found at